InferTrust™ supports compliance with HIPAA, SOX, GDPR, PCI-DSS, and FDA SaMD guidance, each requiring cryptographic proof that AI decisions are unaltered and do
InferTrust™ (Patent Pending) is designed to support compliance with multiple regulatory frameworks that impose requirements on AI decision documentation, data integrity,and auditability. While InferTrust™ does not replace legal counsel or compliance programs, it provides the technical infrastructure needed to satisfy the evidentiary requirements these regulations impose.
The Health Insurance Portability and Accountability Act requires covered entities to maintain the integrity and confidentiality of protected health information. InferTrust™'s cryptographic decision records provide tamper-evident documentation of AI decisions involving PHI, while its architecture keeps PHI within the organization's control boundary.
SOX requires publicly traded companies to maintain reliable internal controls over financial reporting. When AI systems are used in financial analysis, reporting, or audit processes, InferTrust™ provides cryptographic proof that AI outputs were not altered between generation and use in financial statements.
The General Data Protection Regulation grants individuals the right to meaningful information about the logic involved in automated decisions. InferTrust™'s comprehensive decision records,including model version, input references,and confidence scores,provide the documentation needed to fulfill transparency obligations under Articles 13, 14,and 22.
The Payment Card Industry Data Security Standard requires organizations to maintain audit trails for system components. When AI systems process or influence decisions involving payment card data, InferTrust™ provides tamper-evident records that satisfy PCI-DSS audit trail requirements.
The FDA's framework for Software as a Medical Device emphasizes transparency, traceability,and clinical validation of AI systems used in medical settings. InferTrust™'s model version tracking, decision-level traceability,and tamper-evident records align with the FDA's expectations for AI-based medical devices.